Galantamine: Reversible Cholinesterase Inhibitor in Alzheimer Dementia

Galantamine is a tertiary alkaloid derived from bulb leaves of various snowdrop species (Galanthus woronowii, later synthesized semi-synthetically). The active ingredient was isolated in Bulgaria in the 1950s and has been approved in the European Union since 2001 as galantamine hydrobromide for the treatment of mild to moderate Alzheimer dementia. Well-known brand names include Reminyl, Galnora, and numerous generic formulations.

Unlike the purely cholinergic active ingredients donepezil or rivastigmine, galantamine has a dual mechanism of action. It not only inhibits acetylcholinesterase but also positively allosterically modulates nicotinic acetylcholine receptors. This dual action is discussed as a possible advantage in symptom control, but clear clinical superiority over donepezil or rivastigmine could not be demonstrated in direct comparison studies. For patients and families, this means that the choice between cholinesterase inhibitors depends primarily on tolerability, formulation, and comorbidities.

Mechanism of Action

In Alzheimer dementia, cholinergic neurons in the nucleus basalis of Meynert deteriorate early. The resulting acetylcholine deficiency in the hippocampus and cortex correlates with deterioration of memory, attention, and activities of daily living. Galantamine intervenes at two points in this cholinergic deficit loop.

First, it competitively and reversibly inhibits acetylcholinesterase in the synaptic cleft. Acetylcholine remains available longer and can more strongly stimulate postsynaptic muscarinic and nicotinic receptors. Second, galantamine binds to an allosteric site on the nicotinic acetylcholine receptor (APL effect, allosteric potentiating ligand) and sensitizes it to its endogenous signal. This modulation has a particular effect on presynaptic acetylcholine release.

Galantamine is metabolized hepatically via CYP2D6 and CYP3A4, with a half-life of approximately seven hours. The extended-release formulation allows once-daily dosing.

Indications

• Mild to moderate Alzheimer type dementia: primary indication (MMSE 10 to 26)
• Mixed dementia with vascular component: off-label, supported by subgroup analyses
• Lewy body dementia and Parkinson dementia: off-label, rivastigmine is often preferred
• Vascular dementia alone: not approved, efficacy uncertain

Galantamine is not approved for severe dementia (MMSE below 10), where memantine is typically used.

Dosage and Administration

Initial dose: 8 mg once daily (extended-release) or 4 mg twice daily (standard form) for four weeks. Target dose: gradual increase in four-week intervals to 16 mg, possibly to 24 mg daily. Higher doses usually bring only more side effects without clear additional benefit.

Take with breakfast, sufficient fluids. In impaired renal function (eGFR 9 to 60 ml/min), maximum dose is 16 mg. In moderate hepatic insufficiency (Child Pugh 7 to 9), maximum dose is 16 mg. Contraindicated in eGFR below 9 ml/min or severe hepatic insufficiency.

Side Effects

Very common to common: nausea, vomiting, diarrhea, loss of appetite, weight loss, fatigue, dizziness, headache, sleep disturbances, nightmares.

Uncommon: bradycardia, AV block, syncope, falls with fracture risk, tremor, muscle cramps, dehydration-related impairment of renal function. Rarely Stevens Johnson syndrome or acute generalized exanthematous pustulosis.

Important: Cholinergic effects can cause falls, incontinence, and bradycardia. An ECG should be considered before starting therapy to identify pre-existing AV blocks. Slow dose titration significantly reduces gastrointestinal side effects.

Drug Interactions

• Anticholinergics (oxybutynin, amitriptyline, diphenhydramine): largely reverse the effect of galantamine, should be avoided if possible
• Beta-blockers and digoxin: additive bradycardia, risk of AV block
• Succinylcholine and other muscle relaxants: prolonged neuromuscular blockade, pre-anesthetic discussion required
• CYP3A4 inhibitors (ketoconazole, erythromycin): increase galantamine levels by up to 40 percent
• CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion): similar level increase
• NSAIDs: increased risk of gastrointestinal ulcers due to enhanced acid secretion

Special Notes

Pregnancy and breast-feeding: not approved, as Alzheimer dementia in childbearing age is a rarity. Animal data show embryotoxicity at high doses.

Anesthesia: patients and anesthesiologists must be informed of ongoing galantamine therapy, as depolarizing muscle relaxants may have prolonged effects.

Treatment goal and course: on average, galantamine slows cognitive decline over six to twelve months but cannot halt the progression. Efficacy assessment is performed after three to six months using MMSE/MoCA, ADL scales, and subjective impression of family members. If deterioration occurs despite therapy and with transition to severe dementia, a switch to memantine or combination therapy is discussed.

Discontinuation: slow tapering is not strictly required, but in practice an abrupt stop is often experienced as a cognitive decline. Gradual reduction over two to four weeks is common.

You might also be interested in

• Donepezil, the most common cholinesterase inhibitor
• Donezepil, common spelling variant of donepezil
• Rivastigmine, alternative oral and transdermal therapy
• Memantine, NMDA receptor antagonist for moderate to severe dementia
• Acetylcholine, the central neurotransmitter

Frequently Asked Questions

Sources

• EMA, Reminyl (Galantamine) EPAR
• AWMF S3 Guideline Dementia (DGN, DGPPN)
• Gelbe Liste, Galantamine Active Ingredient Profile
• BfArM, Federal Institute for Drugs and Medical Devices